• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein
(LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse …

Abstract Background Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial
lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Background Drug combinations rather than increasing doses of one drug can achieve
greater efficacy and lower risks. Thus, as an alternative to high-intensity statin monotherapy …

The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …